Mometasone to remain a mostly prescription product after downscheduling application is knocked back TGA regulators have rejected a proposal to move the corticosteroid mometasone to become a Schedule 3 product. It was decided that diagnosis, management and monitoring of the medical condition was such that it required medical intervention before mometasone was used. Mometasone remains
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.